Protagenic Therapeutics, Inc.\new

Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of Teneurin Carboxy-terminal Associated Peptide-1 (TCAP-1), designed to counter excess stress signaling. The company targets conditions including treatment-resistant depression, substance use disorder, generalized anxiety disorder, and post-traumatic stress disorder. Through a prior reverse merger with Phytanix Bio, historical drug candidate programs also encompass preclinical assets such as potassium channel modulators, cannabinoid-based therapies, and modified stilbenoid compounds.

The company operates as a clinical-stage development entity with human clinical studies for its lead drug candidate. Its principal executive offices are located in New York, New York. Intellectual property rights for its primary platform are maintained through licensing agreements with the University of Toronto. International research and patent activities also extend to jurisdictions such as Canada, the United Kingdom, and Europe.

Summary of the business section of Protagenic Therapeutics, Inc.\new's latest annual report, written by StockData.

“We currently have two full-time and one part-time employees. We also engage consultants and temporary employees from time to time to provide services that relate to our research a”